Cooperative Agreement R44CA183203

Visikol Inc. received a $4,103,265 Project Grant award from the National Cancer Institute, a division of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will support the development of a 3D imaging diagnostic tool to improve characterization of metastatic melanoma in sentinel lymph node biopsies. Visikol will conduct a retrospective clinical study using archived negative sentinel lymph node biopsy tissue blocks to...

Federal Cooperative Agreement Award Summary The Beckman Research Institute of the City of Hope received a $738,675 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop an innovative exosome-based liquid biopsy assay for the non-invasive early detection of colorectal adenomas and cancers. Awarded on March 16, 2026, with a completion date of February 28, 2031, this five-year project addresses a critical...

Federal Cooperative Agreement Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $225,511 Cooperative Agreement award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective March 16, 2026, with a completion date of February 29, 2028. The award supports the development and validation of a plasma-based multimodal digital polymerase chain reaction (PCR) assay to detect androgen receptor (AR) somatic...

Federal Cooperative Agreement Summary Yale University received a $251,360 Cooperative Agreement award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the project "Multiplexed Spatially Resolved Tissue Biomarkers for Optimal Use of PD-1 Axis Blockers and PARP Inhibitors in Cancer," effective September 1, 2025 through August 31, 2027. The project will develop and analytically validate two multiplex quantitative...

Cancer Immunoprevention Network Resource Coordinating Center Health Research, Inc. (Roswell Park Division) received a $1.65 million Cooperative Agreement from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) beginning September 1, 2025, through August 31, 2030. The awardee will serve as the Data and Resource Coordinating Center (DRCC) for the Cancer Immunoprevention Network (CIP-NET), providing centralized administrative infrastructure, data...

Federal Cooperative Agreement Summary The University of Michigan received a $210,600 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective September 1, 2025 through August 31, 2027. The award supports the analytical and clinical validation of an H3K27M circulating tumor DNA (ctDNA) assay for diffuse midline glioma (DMG) surveillance. The project addresses a critical clinical need by developing a...

Cooperative Agreement Summary The University of California, Davis received a $715,222 Cooperative Agreement awarded May 22, 2025, under the Trans-NIH Research Support program (CFDA 93.310) from the National Institutes of Health Office of the Director. The project, "Validated Immunoassays to Accelerate Therapeutic Genome Editing INDs," will deliver two primary validated assay platforms designed to support the safe clinical translation of somatic cell genome editing therapies. The...

Federal Cooperative Agreement Summary Mayo Clinic received a $266,736 Cooperative Agreement awarded August 1, 2025, by the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to validate a novel liquid biopsy-based assay for monitoring high-grade gliomas. The project focuses on technical and clinical validation of a circulating tumor DNA (ctDNA) plasma test that detects amplified genomic chromosomal junctions unique to individual patients' tumors....

Federal Cooperative Agreement Summary The University of Pittsburgh received a $360,643 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025, through August 31, 2030. This award supports preanalytical validation research for circulating tumor DNA (ctDNA) and tumor-derived exosomes (TEX) as biomarkers of postoperative minimal residual disease (MRD) in head and neck squamous cell carcinoma (HNSCC)....

The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...